DLC1 and cancer: One limitation of this therapeutic approach is that it is only likely to benefit tumors with moderate to high levels of DLC1 protein, and DLC1 expression is frequently downregulated in a variety of cancers through genetic and non-genetic mechanisms6,9–13.